These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1489 related items for PubMed ID: 14727993

  • 1. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K.
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.
    Klein L, O'Connor CM, Gattis WA, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M.
    Am J Cardiol; 2003 May 08; 91(9A):18F-40F. PubMed ID: 12729848
    [Abstract] [Full Text] [Related]

  • 3. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS.
    J Lab Clin Med; 2001 May 08; 137(5):316-23. PubMed ID: 11329528
    [Abstract] [Full Text] [Related]

  • 4. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN, A-HeFT Investigators.
    Am J Cardiovasc Drugs; 2007 May 08; 7(5):373-80. PubMed ID: 18041162
    [Abstract] [Full Text] [Related]

  • 5. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B.
    Pol Merkur Lekarski; 1999 Mar 08; 6(33):152-6. PubMed ID: 10365602
    [Abstract] [Full Text] [Related]

  • 6. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
    Sigurdsson A, Swedberg K.
    Eur Heart J; 1995 Dec 08; 16 Suppl N():65-72. PubMed ID: 8682064
    [Abstract] [Full Text] [Related]

  • 7. The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure.
    Levine TB, Levine AB, Keteyian SJ, Narins B.
    Clin Cardiol; 1998 Dec 08; 21(12):899-904. PubMed ID: 9853182
    [Abstract] [Full Text] [Related]

  • 8. Medical advances in the treatment of congestive heart failure.
    Armstrong PW, Moe GW.
    Circulation; 1993 Dec 08; 88(6):2941-52. PubMed ID: 7902784
    [Abstract] [Full Text] [Related]

  • 9. Medical management of mild-to-moderate heart failure before the advent of beta blockers.
    Abraham WT, Wagoner LE.
    Am J Med; 2001 May 07; 110 Suppl 7A():47S-62S. PubMed ID: 11334776
    [Abstract] [Full Text] [Related]

  • 10. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF.
    Am J Health Syst Pharm; 2004 May 01; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [Abstract] [Full Text] [Related]

  • 11. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS.
    Pharmacotherapy; 1993 May 01; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [Abstract] [Full Text] [Related]

  • 12. Optimizing the treatment of heart failure.
    Giles TD.
    Curr Opin Cardiol; 1994 Jul 01; 9 Suppl 1():S21-7. PubMed ID: 7827370
    [Abstract] [Full Text] [Related]

  • 13. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
    Ahmed A.
    J Am Geriatr Soc; 2003 Jan 01; 51(1):123-6. PubMed ID: 12534856
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 01; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 15. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A.
    Blood Press Suppl; 1995 Oct 01; 1():1-45. PubMed ID: 7599749
    [Abstract] [Full Text] [Related]

  • 16. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul 01; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 17. ACE inhibitors in heart failure: what more do we need to know?
    Demers C, Mody A, Teo KK, McKelvie RS.
    Am J Cardiovasc Drugs; 2005 Jul 01; 5(6):351-9. PubMed ID: 16259523
    [Abstract] [Full Text] [Related]

  • 18. Medical therapy and prognosis in chronic heart failure. Lessons from clinical trials.
    Ramahi TM, Lee FA.
    Cardiol Clin; 1995 Feb 01; 13(1):5-26. PubMed ID: 7796432
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II receptor blockers in the treatment of heart failure.
    Peterson RC, Dunlap ME.
    Congest Heart Fail; 2002 Feb 01; 8(5):246-50; 256. PubMed ID: 12368586
    [Abstract] [Full Text] [Related]

  • 20. The management of heart failure--an overview.
    Erdmann E.
    Basic Res Cardiol; 2000 Feb 01; 95 Suppl 1():I3-7. PubMed ID: 11192349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.